Pierre Fabre Medicament

Ablexis, LLC

Pfizer Corporation

Beijing Xuanyi Pharmasciences Co., Ltd.

John Lippincott

Leonard G Presta

Edward Thein Htun Van Der Horst

Sun Young Kim

Jan-Willem Theunissen

Dana Duey

Sung Young Kim

Yi Ding

Yuntao Song

Donna Marie Stone

Ping Wei

Leonard Presta

Chen Dong

Ping Hui Szu

Kang Li

Qinghai Peng

Zdenek Hostomsky

Zhiwei Li

Edward Thein Van Der Horst

The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.

Anti-C10orf54 antibodies and uses thereof

The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.

Anti-CD115 antibodies

Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.

Anti-claudin 18.2 antibodies

Anti-C10ORF54 antibodies and uses thereof

This invention is directed toward monoclonal antibodies that bind specifically to Notch1. In one embodiment, the antibodies binds to at least a first epitope and a second epitope, wherein the first epitope resides with the LinA domain of the Notch1 negative regulatory region (NRR), and the second epitope resides within the HD-C domain of the Notch1 NRR.

Anti Notch-1 antibodies

Growing community of inventors

San Mateo, CA, United States of America

John Lippincott